BOSTON and EDINBURGH, Scotland--(BUSINESS WIRE)--March 10, 2005--According to Medicare Insight(TM), a landmark study by Wood Mackenzie, reforms to Medicare have put many large pharmaceutical companies at risk of their blockbuster products not being included within new Part D drug benefit plans being designed for launch in January 2006.
In 2004 the Medicare market accounted for almost 50% of the US pharmaceutical market of $240 billion (Wood Mackenzie estimates) making it the second largest drug market in the world, with revenues bigger than the whole of Japan. If government plans for Medicare reform succeed, Part D plans could cover up to three quarters of the total Medicare population of 41 million.
